Last reviewed · How we verify
arginine/lysine
Arginine and lysine are amino acids that support immune function and may enhance natural killer cell activity and protein synthesis.
Arginine and lysine are amino acids that support immune function and may enhance natural killer cell activity and protein synthesis. Used for Immune support (specific indication unclear).
At a glance
| Generic name | arginine/lysine |
|---|---|
| Also known as | LysaKare |
| Sponsor | Advanced Accelerator Applications |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Arginine is a semi-essential amino acid involved in nitric oxide production, immune cell proliferation, and wound healing. Lysine is an essential amino acid that plays roles in collagen formation and immune response. Together, they may support immune function, though the specific mechanism for any marketed formulation by Advanced Accelerator Applications is not well-established in standard pharmaceutical literature.
Approved indications
- Immune support (specific indication unclear)
Common side effects
- Gastrointestinal upset
- Nausea
Key clinical trials
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs (PHASE2)
- RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma (PHASE1, PHASE2)
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (PHASE1)
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (EARLY_PHASE1)
- Prandial Metabolic Phenotype in Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- arginine/lysine CI brief — competitive landscape report
- arginine/lysine updates RSS · CI watch RSS
- Advanced Accelerator Applications portfolio CI